Abstract:Despite the current promise of immunotherapy, many cancer patients still suffer from challenges such as poor immune response rates, resulting in unsatisfactory clinical efficacy of existing therapies. There is an urgent need to combine emerging biomedical discoveries and innovations in traditional therapies. Modulation of the cGAS-STING signalling pathway represents an important innate immunotherapy pathway that serves as a crucial DNA sensing mechanism in innate immunity and viral defense. It has attracted increasing attention as an emerging target for cancer therapy. The recent advancements in nanotechnology have led to the significant utilization of nanomaterials in cancer immunotherapy, owing to their exceptional physicochemical properties such as large specific surface area and efficient permeability. Given the rapid development of cancer immunotherapy driven by the cGAS-STING activation, this study reviews the latest research progress in employing nanomaterials to modulate this signaling pathway. Based on the introduction of the main activation mechanisms of cGAS-STING pathway, this review focuses on nanomaterials that mediate the agonists involved and effectively activate this signaling pathway. In addition, combination nanotherapeutics based on the activation of the cGAS-STING signaling pathway are also discussed, including emerging strategies combining nanoformulated agonists with chemotherapy, radiotherapy as well as other immunomodulation in tumor targeting therapy. Statement of Significance Given the rapid development of cancer immunotherapy driven by the cGAS / STING activation, this study reviews the latest research advances in the use of nanomaterials to modulate this signaling pathway. Based on the introduction of key cGAS-STING components and their activation mechanisms, this review focuses on nanomaterials that can mediate the corresponding agonists and effectively activate this signaling pathway. In addition, combination nanotherapies based on the activation of the cGAS-STING signaling pathway are also discussed, including emerging strategies combining nanoformulated agonists with chemotherapy, radiotherapy as well as immunomodulation in cancer therapy,.

Targeting Activation of Cgas-Sting Signaling Pathway by Engineered Biomaterials for Enhancing Cancer Immunotherapy

Nanomaterial-mediated modulation of the cGAS-STING signaling pathway for enhanced cancer immunotherapy

Cell-to-cell communications of cGAS-STING pathway in tumor immune microenvironment.

Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies

cGAS-STING pathway in cancer biotherapy

Metal-based Nanoparticles Promote the Activation of Cgas-Sting Pathway for Enhanced Cancer Immunotherapy

Enhancing immunotherapy outcomes by targeted remodeling of the tumor microenvironment via combined cGAS-STING pathway strategies

Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy

Recent Progress in Photothermal, Photodynamic and Sonodynamic Cancer Therapy: Through the cGAS-STING Pathway to Efficacy-Enhancing Strategies

Nanoparticle‐Mediated STING Activation for Cancer Immunotherapy

Tumor-responsive Covalent Organic Polymeric Nanoparticles Enhancing STING Activation for Cancer Immunotherapy

Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway

The multiple faces of cGAS-STING in antitumor immunity: prospects and challenges

Advanced nanomaterials targeting activation of STING for enhanced cancer immunotherapy

cGAS-STING Pathway as the Target of Immunotherapy for Lung Cancer

Therapeutic targeting of cGAS–STING pathway in lung cancer

Engineering and Delivery of cGAS-STING Immunomodulators for the Immunotherapy of Cancer and Autoimmune Diseases

Synthetic Enforcement of STING Signaling in Cancer Cells Appropriates the Immune Microenvironment for Checkpoint Inhibitor Therapy.

Targeting STING signaling for the optimal cancer immunotherapy

Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy

Strategies involving STING pathway activation for cancer immunotherapy: mechanism and agonists